Related Experiment Video
Updated: Mar 1, 2026
04:29
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
29.7K
Vagal Nerve Stimulation for Treatment-Resistant Depression
Flavia R Carreno1,2, Alan Frazer3,4,5
1Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. carrenof@uthscsa.edu.
Summary
Vagus nerve stimulation (VNS) shows promise for treatment-resistant depression (TRD) when conventional antidepressants fail. Open studies suggest increasing efficacy over time, though more research is needed.
Area of Science:
- Neuroscience
- Psychiatry
- Medical Devices
Background:
- Major depressive disorder (MDD) affects many, with a significant portion experiencing treatment resistance (TRD).
- Current antidepressants are not effective for all patients with TRD.
- Vagus nerve stimulation (VNS) is an FDA-approved treatment for TRD.
Purpose of the Study:
- To review the efficacy and potential mechanisms of vagus nerve stimulation (VNS) for treatment-resistant depression (TRD).
Main Methods:
- Review of existing literature on VNS for TRD, including open studies and brain imaging.
- Analysis of VNS effects on neurotransmitters and brain pathways.
- Comparison of VNS efficacy with standard antidepressant treatments.
Main Results:
- Open studies indicate increasing clinical response to VNS between 3 and 12 months.
- VNS affects brain areas and neurotransmitters similar to traditional antidepressants.
- Brain imaging reveals widespread functional changes following VNS.
Conclusions:
- VNS demonstrates potential efficacy for TRD, with a delayed response compared to standard antidepressants.
- Further randomized controlled trials are necessary to definitively establish VNS efficacy.
- The precise mechanisms underlying VNS benefits in TRD remain unclear and require further investigation.
